Cargando…

Identification of the first COVID-19 infections in the US using a retrospective analysis

Accurate detection of early COVID-19 cases is crucial to drastically reduce infection, hospitalization, and death rates. However, it remains a challenge and methods for identifying initial COVID-19 cases are urgently needed. Here, we used the results from a seroprevalence study in 50 US states to ap...

Descripción completa

Detalles Bibliográficos
Autores principales: García-García, David, Morales, Enrique, de la Fuente-Nunez, Cesar, Vigo, Isabel, Fonfría, Eva S., Bordehore, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312904/
https://www.ncbi.nlm.nih.gov/pubmed/34312619
http://dx.doi.org/10.21203/rs.3.rs-707353/v1
_version_ 1783729221621776384
author García-García, David
Morales, Enrique
de la Fuente-Nunez, Cesar
Vigo, Isabel
Fonfría, Eva S.
Bordehore, Cesar
author_facet García-García, David
Morales, Enrique
de la Fuente-Nunez, Cesar
Vigo, Isabel
Fonfría, Eva S.
Bordehore, Cesar
author_sort García-García, David
collection PubMed
description Accurate detection of early COVID-19 cases is crucial to drastically reduce infection, hospitalization, and death rates. However, it remains a challenge and methods for identifying initial COVID-19 cases are urgently needed. Here, we used the results from a seroprevalence study in 50 US states to apply our Retrospective Methodology to Estimate Daily Infections from Deaths (REMEDID) with the aim of analyzing the initial stages and spread of SARS-CoV-2 infections across the United States (US). Our retrospective data analysis revealed that the virus likely entered the country through California on December 28, 2019, which corresponds to 16 days before the officially recognized entry date established by the CDC. Thus, REMEDID provides evidence that SARS-CoV-2 entered the U.S. earlier than previously reflected in official data. Collectively, our mathematical modeling more accurately estimates the initial COVID-19 cases in the US, may be extrapolated to other countries, and may be used to retrospectively track the progress of the pandemic. Approaches such as REMEDID may enable health authorities to accelerate preventative measures aimed at controlling pandemics within weeks of their onset.
format Online
Article
Text
id pubmed-8312904
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Journal Experts
record_format MEDLINE/PubMed
spelling pubmed-83129042021-07-27 Identification of the first COVID-19 infections in the US using a retrospective analysis García-García, David Morales, Enrique de la Fuente-Nunez, Cesar Vigo, Isabel Fonfría, Eva S. Bordehore, Cesar Res Sq Article Accurate detection of early COVID-19 cases is crucial to drastically reduce infection, hospitalization, and death rates. However, it remains a challenge and methods for identifying initial COVID-19 cases are urgently needed. Here, we used the results from a seroprevalence study in 50 US states to apply our Retrospective Methodology to Estimate Daily Infections from Deaths (REMEDID) with the aim of analyzing the initial stages and spread of SARS-CoV-2 infections across the United States (US). Our retrospective data analysis revealed that the virus likely entered the country through California on December 28, 2019, which corresponds to 16 days before the officially recognized entry date established by the CDC. Thus, REMEDID provides evidence that SARS-CoV-2 entered the U.S. earlier than previously reflected in official data. Collectively, our mathematical modeling more accurately estimates the initial COVID-19 cases in the US, may be extrapolated to other countries, and may be used to retrospectively track the progress of the pandemic. Approaches such as REMEDID may enable health authorities to accelerate preventative measures aimed at controlling pandemics within weeks of their onset. American Journal Experts 2021-07-24 /pmc/articles/PMC8312904/ /pubmed/34312619 http://dx.doi.org/10.21203/rs.3.rs-707353/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
García-García, David
Morales, Enrique
de la Fuente-Nunez, Cesar
Vigo, Isabel
Fonfría, Eva S.
Bordehore, Cesar
Identification of the first COVID-19 infections in the US using a retrospective analysis
title Identification of the first COVID-19 infections in the US using a retrospective analysis
title_full Identification of the first COVID-19 infections in the US using a retrospective analysis
title_fullStr Identification of the first COVID-19 infections in the US using a retrospective analysis
title_full_unstemmed Identification of the first COVID-19 infections in the US using a retrospective analysis
title_short Identification of the first COVID-19 infections in the US using a retrospective analysis
title_sort identification of the first covid-19 infections in the us using a retrospective analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312904/
https://www.ncbi.nlm.nih.gov/pubmed/34312619
http://dx.doi.org/10.21203/rs.3.rs-707353/v1
work_keys_str_mv AT garciagarciadavid identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis
AT moralesenrique identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis
AT delafuentenunezcesar identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis
AT vigoisabel identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis
AT fonfriaevas identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis
AT bordehorecesar identificationofthefirstcovid19infectionsintheususingaretrospectiveanalysis